IPO Update: With No New Offerings, Kadmon Steals The Spotlight
Executive Summary
Initial public offering activity has been slow as the summer kicks into high gear, but a filing with SEC by Kadmon has peculiarities that promise high drama the likes of which only Sam Waksal could offer.
You may also be interested in...
IPO Update: Protagonist, Gemphire, Kadmon Launches Fall Flat
The three most recent biopharma IPOs are trading at or below their offering prices, but the average return for the 22 drug development firms that have gone public so far this year is holding steady at 11% -- thanks to a pair of super performers that have delivered triple-digit returns.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours
It hasn't been easy for biopharmaceutical firms to go public in the US during 2016, but as of the end of June the scrutiny seems to be paying off – at least for investors in half of this year's first-half initial public offerings.
Need a specific report? 1000+ reports available
Buy Reports
